Defense Tech Patent Shield Narrowed: Impact on ‘Neoprimes’ & Section 1498 Immunity

The Shifting Sands of Defense Contractor Immunity: A $2.25 Billion Settlement and Its Implications

For over a century, U.S. Law has shielded defense contractors from patent lawsuits when manufacturing for the government. But a recent $2.25 billion settlement between Arbutus Biopharma and Moderna, stemming from a dispute over COVID-19 vaccine technology, is challenging the boundaries of that protection. This case isn’t about weapons systems; it’s about the evolving nature of defense technology and the rise of “neoprimes” – companies building dual-use technologies for both military and commercial applications.

A Century of Protection: 28 U.S.C. § 1498

The legal foundation for this protection lies in 28 U.S.C. § 1498. Originally enacted in 1910 and expanded in 1918, the law was designed to prevent patent litigation from disrupting wartime production. It stipulates that if a contractor uses or manufactures a patented invention “for the Government and with the authorization or consent of the Government,” the patent holder’s recourse is to sue the U.S. Government directly, not the contractor. This immunity has been broadly interpreted over the decades, even extending to products manufactured abroad.

The Moderna Case: A Narrowing of Immunity

Moderna invoked this immunity in a Delaware federal court, arguing that its COVID-19 vaccine was developed under a government contract (Operation Warp Speed) with explicit authorization. But, the court rejected this argument for the vast majority of vaccine sales. The key ruling hinged on the definition of “for the Government.” The court determined that the benefit must accrue directly to the government itself, not the broader public. Since most vaccine doses were administered to citizens, not government employees, Moderna’s immunity was limited to a small fraction of doses.

This ruling introduces a critical distinction: government funding and authorization alone are no longer sufficient to guarantee immunity. The end-use of the product matters.

The $2.25 Billion Settlement and Pending Appeal

The parties reached a $2.25 billion global settlement, with $1.3 billion contingent on the outcome of an appeal to the U.S. Court of Appeals for the Federal Circuit. This appeal will directly address the interpretation of “for the Government” in Section 1498, and the Federal Circuit’s decision will have nationwide implications.

Why Neoprimes Should Be Concerned

The Department of Defense is increasingly reliant on neoprimes – companies like Anduril, Palantir, and Shield AI – to rapidly develop cutting-edge technologies using private investment. These firms often create platforms with both military and commercial applications. The Delaware court’s reasoning poses a significant risk to this model.

Consider an AI-powered autonomous system used for base security and civilian disaster relief. If the court’s narrow interpretation of “for the Government” prevails, the company could be shielded from litigation in the military application but exposed in the civilian one. This uncertainty is particularly problematic because neoprimes often develop these platforms *before* securing formal government contracts.

A recent case involving AeroVironment, a defense contractor, offered a contrasting outcome. They successfully invoked Section 1498 in a case related to promotional demonstrations of a helicopter, but the facts were distinct – the demonstrations weren’t considered commercial conduct.

A Historical Pattern of Congressional Adjustments

Section 1498 has been amended several times throughout history to address evolving needs. Congress expanded the statute in 1918 after a Supreme Court ruling limited its scope, and again in 1942 to ensure uninterrupted wartime production.

Currently, Congress is developing the Fiscal Year 2027 National Defense Authorization Act. While recent legislation has focused on lowering barriers for nontraditional defense contractors, it hasn’t addressed the issue of patent immunity. A clarifying amendment to Section 1498, specifying that government-authorized development qualifies for immunity regardless of end-use, could provide much-needed certainty.

FAQ

Q: What is Section 1498 immunity?
A: It’s a legal protection that shields defense contractors from patent lawsuits when they are manufacturing products for the U.S. Government with government authorization.

Q: What was the key issue in the Moderna case?
A: The court determined that the benefit of the vaccine had to accrue directly to the government, not the public, to qualify for immunity.

Q: What are “neoprimes”?
A: These are emerging defense companies that use private funding to develop dual-use technologies for both military and commercial applications.

Q: Could Congress address this issue?
A: Yes, Congress could amend Section 1498 to clarify the scope of immunity and provide greater certainty for defense contractors.

Did you grasp? The original Section 1498 legislation was a direct response to concerns from the Navy about contractors being hesitant to build equipment due to potential patent litigation.

Pro Tip: Defense contractors developing dual-use technologies should carefully assess their potential patent litigation risk and consider seeking legal counsel to navigate this evolving landscape.

This case highlights a critical tension between protecting intellectual property rights and fostering innovation in the defense sector. The outcome of the appeal will shape the future of defense procurement and the role of neoprimes in national security.

Explore more insights on defense technology and legal challenges at [Link to other relevant article on the website].